Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1

J Joshua E. Reuss (Georgetown University, Washington, DC) N Nofisat Ismaila (American Society of Clinical Oncology (ASCO), Alexandria, VA, US) A Amith Ahluwalia (Confluence Health Wenatchee Valley Hospital and Clinics, Wenatchee, WA) T Toby Campbell (University of Wisconsin, Madison, WI) J Jill Feldman (Patient Advocate EGFR Resisters Deerfield Illinois USA) S Shirish Gadgeel (Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI) M Michael Mullane (Aurora Cancer Care, Mount Pleasant, WI) C Carolyn J. Presley E Eric K. Singhi (University of Texas MD Anderson Cancer Center, Houston, TX) J Jennifer Marie Suga (Kaiser Permanente Vallejo Medical Center, Vallejo, CA) S Sonam Puri

Abstract

This guideline has been updated. This ASCO Living Guideline is reviewed on an eight-week cycle. Please see the online dynamic version for the latest updates. Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix 1 and Appendix 2 , online only). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline .

Article Details

Volume / Issue Vol. 44, Issue 18
Published June 20, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (11)

J

Joshua E. Reuss

Georgetown University, Washington, DC

N

Nofisat Ismaila

American Society of Clinical Oncology (ASCO), Alexandria, VA, US

A

Amith Ahluwalia

Confluence Health Wenatchee Valley Hospital and Clinics, Wenatchee, WA

T

Toby Campbell

University of Wisconsin, Madison, WI

J

Jill Feldman

Patient Advocate EGFR Resisters Deerfield Illinois USA

S

Shirish Gadgeel

Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI

M

Michael Mullane

Aurora Cancer Care, Mount Pleasant, WI

C

Carolyn J. Presley

E

Eric K. Singhi

University of Texas MD Anderson Cancer Center, Houston, TX

J

Jennifer Marie Suga

Kaiser Permanente Vallejo Medical Center, Vallejo, CA

S

Sonam Puri